Memristors can be used to mimic synaptic behavior in artificial neural networks, which makes them a key component in neuromorphic computing and holds promise for advancing the field. In this study, a ...

Chronic nerve block did not prevent synapse elimination. The first signs of reinnervation of partially denervated 4DL by SN motor axons were observed no earlier than 15 days after nerve crush 11 ...

Synapse ITS, a portfolio company of Vance Street Capital, has acquired GovComm, Florida-based traffic technology company specializing in wrong-way vehicle detection systems. No financial terms ...

Captagon, a powerful amphetamine, has fueled a booming illicit industry in Syria over the past decade. With the war crippling the formal economy, the country became the world’s largest narco-state ...

Organic photonic synaptic devices have shown immense potential for emulating the visual perception function of the human retina. In particular, organic electrochemical transistors (OECTs) with ...

At synapses, miniature synaptic transmission forms the basic unit of evoked transmission, thought to use one canonical transmission site. Two general types of synaptic plasticity, associative ...

Self-powered artificial synapse mimics human color vision Date: June 2, 2025 Source: Tokyo University of Science Summary: Despite advances in machine vision, processing visual data requires ...

As artificial intelligence and smart devices continue to evolve, machine vision is taking an increasingly pivotal role as a key enabler of modern technologies. Unfortunately, despite much progress, ...

“Originally, astrocytes were believed to just clean up around neurons, but there’s no particular reason that evolution did not realize that, because each astrocyte can contact hundreds of thousands of ...

Current treatments for dopamine-related conditions use agents that can either block or enhance dopamine signaling, such as stimulants used to treat attention-deficit/hyperactivity disorder, including ...

Syndeio Biosciences launches with molecules to target the synapse Company’s lead candidate is already in a Phase 2 trial for major depressive disorder by Sarah Braner ...